<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837015</url>
  </required_header>
  <id_info>
    <org_study_id>CTN308</org_study_id>
    <nct_id>NCT03837015</nct_id>
  </id_info>
  <brief_title>Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women</brief_title>
  <official_title>Improving Vaginal Health to Decrease Biological Risk of HIV-1 Infection in Canadian African, Caribbean and Black (ACB) Women: Estrogen and Probiotic Treatment for Vaginal Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enrol African, Caribbean and Black (ACB) women who are known to have a more&#xD;
      diverse vaginal microbiome, higher rates of bacterial vaginosis with lower numbers of&#xD;
      protective lactobacilli, and are at increased risk for HIV. The investigators will evaluate&#xD;
      the safety, feasibility, effect on the vaginal bacterial microbiome and changes in local&#xD;
      immune and inflammatory responses with the administration of vaginal estrogen alone, vaginal&#xD;
      estrogen in combination with oral or vaginally administered probiotics, or vaginal probiotics&#xD;
      alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women are at increased risk of HIV acquisition compared with men. A number of biological&#xD;
      factors are associated with increased risk, many of which likely enhance risk by increasing&#xD;
      inflammation in the female genital tract. Susceptibility to infections and immune responses&#xD;
      in the female genital tract are regulated by hormones: progesterone increases inflammation&#xD;
      and HIV susceptibility and estrogen decreases inflammation and enhances colonization with&#xD;
      Lactobacilli.&#xD;
&#xD;
      A Lactobacillus dominant vaginal microbiome is associated with increased protection against&#xD;
      HIV, while a polymicrobial vaginal flora, as seen in bacterial vaginosis, is associated with&#xD;
      increased risk. About 40% of ACB women have a polymicrobial flora.&#xD;
&#xD;
      The goal of this study is to establish a Lactobacillus dominant vaginal microbiome in ACB&#xD;
      women, that will be associated with decreased inflammation and decreased susceptibility to&#xD;
      HIV, by administering a low level of intravaginal estrogen to increase colonization with&#xD;
      Lactobacilli together with a Lactobacillus-containing probiotic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refusal rate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of eligible participants approached who do not consent to be enrolled</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant retention rate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants who complete the study as proportion of total number of participants enrolled</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>2 months</time_frame>
    <description>The incidence of adverse events, including serious adverse events, their severity and their relationship to study intervention assessed by reviewing case report forms and participant diaries.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adherence</measure>
    <time_frame>30 days</time_frame>
    <description>Adherence will be measured by calculating the total probiotic used/total dispensed and for Estring by total days used/total time period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in proportion of Lactobacillus species in the vaginal microbiota</measure>
    <time_frame>30 days</time_frame>
    <description>Aliquots of cervico-vaginal lavage (CVL) fluids will undergo microbiome analysis using a modified Illumina sequencing method for bacterial community profiling of 16S rRNA to measure changes from baseline at follow-up sampling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in innate inflammatory cytokine/chemokine levels</measure>
    <time_frame>30 days</time_frame>
    <description>Changes from baseline in levels of cytokine/chemokines will be measured in CVL by a 22-plex multiplex assay at 2 and 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in number of HIV target cells in the genital tract</measure>
    <time_frame>30 days</time_frame>
    <description>Changes from baseline in level of HIV susceptible CD4+ T cells will be quantified using a lab developed HIV pseudovirus assay at 2 and 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Bacterial Vaginoses</condition>
  <arm_group>
    <arm_group_label>Estring alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estring and vaginal RepHresh Pro-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estring and oral RepHresh Pro-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal RepHresh Pro-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estring Vaginal Ring</intervention_name>
    <description>Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days</description>
    <arm_group_label>Estring alone</arm_group_label>
    <arm_group_label>Estring and oral RepHresh Pro-B</arm_group_label>
    <arm_group_label>Estring and vaginal RepHresh Pro-B</arm_group_label>
    <other_name>17 beta-estradiol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RepHresh Pro-B</intervention_name>
    <description>Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally</description>
    <arm_group_label>Estring and oral RepHresh Pro-B</arm_group_label>
    <arm_group_label>Estring and vaginal RepHresh Pro-B</arm_group_label>
    <arm_group_label>Vaginal RepHresh Pro-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African, Caribbean, Black&#xD;
&#xD;
          -  Pre-menopausal women in good general health, as determined by the investigator&#xD;
&#xD;
          -  Uterus and cervix present&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Currently practicing barrier or non-hormonal forms of contraception, and planning to&#xD;
             continue, for the duration of the study (barrier contraceptive, abstinence)&#xD;
&#xD;
          -  Willing to undergo a pelvic exam by a female nurse/female doctor&#xD;
&#xD;
          -  Willing to abstain from vaginal intercourse for 48 hours prior to sampling, over the&#xD;
             entire course of the study&#xD;
&#xD;
          -  Able to understand, comply and consent to protocol requirements and instructions&#xD;
&#xD;
          -  Able to attend scheduled study visits and complete required investigations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently lactating&#xD;
&#xD;
          -  Pregnant: suspected, current or in the last 12 months&#xD;
&#xD;
          -  Irregular menstrual cycle (less than 6 periods in a year) not related to contraceptive&#xD;
             use, pregnancy or breastfeeding&#xD;
&#xD;
          -  Post-menopausal&#xD;
&#xD;
          -  Hormonal Contraceptive use or other hormonal treatment in the past 3 months&#xD;
&#xD;
          -  Current Intra-Uterine Device (IUD) use&#xD;
&#xD;
          -  Positive test result for Gonorrhea and/or Chlamydia&#xD;
&#xD;
          -  Clinically obvious genital ulceration/lesions&#xD;
&#xD;
          -  Symptomatic vaginal yeast infection or clinically significant vaginal discharge&#xD;
&#xD;
          -  HIV-positive&#xD;
&#xD;
          -  Any clinically significant abnormality on screening safety blood tests, that in the&#xD;
             opinion of the investigator would preclude enrolment.&#xD;
&#xD;
          -  Diagnosed blood clotting disorder&#xD;
&#xD;
          -  Any genital tract procedure (e.g. biopsy) within the past 6 months&#xD;
&#xD;
          -  Use of oral probiotic supplement, oral antibiotics or oral steroids within the past 30&#xD;
             days&#xD;
&#xD;
          -  Current use of any vaginal products (except tampons) such as spermicides,&#xD;
             microbicides, douching or drying products, antifungals, or steroids.&#xD;
&#xD;
          -  Known intolerance of Lactobacillus-containing probiotic supplements&#xD;
&#xD;
          -  Undiagnosed abnormal genital bleeding&#xD;
&#xD;
          -  Known, suspected, or history of breast cancer&#xD;
&#xD;
          -  Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer)&#xD;
&#xD;
          -  Currently taking immunosuppressive drugs&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any component of the Estring or RepHresh Pro-B&#xD;
             products&#xD;
&#xD;
          -  Diagnosis of endometrial hyperplasia&#xD;
&#xD;
          -  Known liver dysfunction or disease; as long as liver function tests have failed to&#xD;
             return to normal&#xD;
&#xD;
          -  Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial&#xD;
             infarction, coronary heart disease)&#xD;
&#xD;
          -  Partial or complete loss of vision due to ophthalmic vascular disease&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Concomitant medication which in the opinion of the investigator may be associated with&#xD;
             a significant drug interaction with the estrogen in Estring.&#xD;
&#xD;
          -  The conditions below are grounds for exclusion based on the opinion of the&#xD;
             investigator:&#xD;
&#xD;
               1. Risk factors for estrogen dependent tumours, e.g. first degree heredity for&#xD;
                  breast cancer&#xD;
&#xD;
               2. Diabetes mellitus with or without vascular involvement&#xD;
&#xD;
               3. Migraine or (severe) headache&#xD;
&#xD;
               4. Epilepsy&#xD;
&#xD;
               5. A history of, or risk factors for, thromboembolic disorders&#xD;
&#xD;
               6. Systemic lupus erythematosus&#xD;
&#xD;
               7. Otosclerosis&#xD;
&#xD;
               8. Cholelithiasis&#xD;
&#xD;
               9. Leiomyoma (uterine fibroids)&#xD;
&#xD;
              10. Endometriosis&#xD;
&#xD;
              11. A history of endometrial hyperplasia&#xD;
&#xD;
              12. Hypertension&#xD;
&#xD;
              13. Asthma&#xD;
&#xD;
              14. Diagnosed anemia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charu Kaushic, PhD</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>22988</phone_ext>
    <email>kaushic@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fiona Smaill, MB,ChB</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>74190</phone_ext>
    <email>smaill@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Women's Health in Women's Hands</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B1J3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junic Wokuri</last_name>
      <phone>416-263-4897</phone>
      <email>ACBwomen@whiwh.com</email>
    </contact>
    <contact_backup>
      <last_name>Jenna Ratcliffe</last_name>
      <email>ratclij@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jesleen Rana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 8, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

